9887 — Nanjing Leads Biolabs Co Income Statement
0.000.00%
Last trade - 00:00- HK$17.57bn
- HK$16.13bn
- CNY177.26m
Annual income statement for Nanjing Leads Biolabs Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PRESS |
| Standards: | IFRS | IFRS | — |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 8.87 | 0 | 177 |
| Cost of Revenue | |||
| Gross Profit | 5.68 | 0 | 177 |
| Research And Development | |||
| Unusual Expense / Income | |||
| Other Operating Expenses | |||
| Total Operating Expenses | 370 | 295 | 340 |
| Operating Profit | -361 | -295 | -163 |
| Gain / Loss on Sale of Assets | |||
| Total Net Non Operating Interest Income / Expense | |||
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | -362 | -301 | -196 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -362 | -301 | -211 |
| Net Income Before Extraordinary Items | |||
| Net Income | -362 | -301 | -211 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -362 | -301 | -211 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -1.72 | -1.06 | -0.727 |